Statera Biopharma, Inc. Common Stock
STAB
STAB was delisted on the 11th of January, 2023.
29 hedge funds and large institutions have $200K invested in Statera Biopharma, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 9 reducing their positions, and 8 closing their positions.
1.41% less ownership
Funds ownership: 5.93% → 4.52% (-1.4%)
17% less funds holding
Funds holding: 35 → 29 (-6)
44% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 9
45% less capital inflows, than outflows
Capital inflows: $73.5K | Capital outflows: $133K
50% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$55.2K |
| 2 |
Millennium Management
New York
|
+$4.22K |
| 3 |
E
Ergoteles
New York
|
+$3.59K |
| 4 |
HRT Financial
New York
|
+$3.11K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
+$1.87K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$80.5K |
| 2 |
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
-$13K |
| 3 |
Virtu Financial
New York
|
-$13K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$12.2K |
| 5 |
Two Sigma Investments
New York
|
-$5K |
STAB Hedge Fund Activity: Q4 2022 in Review
29 of the 6,243 institutional investors tracked by Wall St. Rank reported a position in Statera Biopharma, Inc. Common Stock (STAB) for Q4 2022, worth a combined $200K — down 48% from $385K a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of STAB and 4 opened new positions — a net loss of 4 holders — while 9 trimmed existing stakes and 5 added.
The largest buyer was Acadian Asset Management, opening a new position worth an estimated $55.2K. The largest seller was Renaissance Technologies, cutting an estimated $80.5K.
- 29 institutional investors held Statera Biopharma, Inc. Common Stock (STAB) as of Q4 2022, down from 35 in Q3 2022.
- Funds reported $200K of Statera Biopharma, Inc. Common Stock stock for Q4 2022, down 48% quarter-over-quarter.
- 4 funds opened new Statera Biopharma, Inc. Common Stock positions in Q4 2022 and 8 closed out, a net change of -4 holders.
- The largest Statera Biopharma, Inc. Common Stock buyer in Q4 2022 was Acadian Asset Management, an estimated $55.2K added.
- The largest Statera Biopharma, Inc. Common Stock seller in Q4 2022 was Renaissance Technologies, an estimated $80.5K sold.
Based on aggregated 13F filings for Q4 2022.